Unknown

Dataset Information

0

Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.

ABSTRACT:

SUBMITTER: Isaacs JT 

PROVIDER: S-EPMC5602292 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.

Isaacs John T JT   Brennen W Nathaniel WN   Denmeade Samuel R SR  

Cell cycle (Georgetown, Tex.) 20170818 18

Similar Datasets

Unknown Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
| S-EPMC9711867 | biostudies-literature
Unknown Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
| S-EPMC10286318 | biostudies-literature
Unknown Bipolar androgen therapy (BAT): A patient's guide.
| S-EPMC9313844 | biostudies-literature
Unknown Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.
| S-EPMC9844588 | biostudies-literature
Unknown Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
| S-EPMC10243791 | biostudies-literature
Unknown Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC.
| S-EPMC9711876 | biostudies-literature
Unknown Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
| S-EPMC10762051 | biostudies-literature
Unknown Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy.
| S-EPMC9774682 | biostudies-literature
Unknown Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss.
| S-EPMC9168525 | biostudies-literature
Genomics Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC
2022-11-01 | GSE213444 | GEO